Non-Small Cell Lung Cancer Pipeline Insight | Non-Small Cell Lung Cancer Pipeline Assessment, Pipeline Drugs

1. Non-Small Cell Lung Cancer Pipeline Insight, Pipeline Assessment, Pipeline Drug "Non-Small Cell Lung Cancer Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer market. A detailed picture of the Non-Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Non-Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces in-depth Non-Small Cell Lung Cancer commercial assessment and clinical assessment of the Non-Small Cell Lung Cancer pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product- related details. NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.

2. Drugs covered in the report are:- There are several key players robustly involved in developing potential products such as                          Nazartinib (EGF816) Capmatinib (INC280) Tepmetko (tepotinib) Merestinib JNJ-61186372 (JNJ-6372) Vemurafenib Plus Cobimetinib X-396 (Ensartinib) Tedopi (OSE2101) Selpercatinib (LY3527723/ LOXO-292) SAR408701 Braftovi (encorafinib) + Mektovi (binimetinib) PADCEV (enfortumab vedotin/ASG-22ME) Pralsetinib (BLU-667) TAK-788: Canakinumab (ACZ885) Avelumab (Bavencio) Veliparib (ABT-888): Sitravatinib (MGCD516) Tesevatinib Romiplostim: Cabozantinib Sym015 AMG 510 INCMGA00012 (MGA012) Libtayo (Cemiplimab) Bavituximab M7824 (Bintrafusp alfa) And many others Request Sample Page @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer- pipeline-insight

3. Key Players covered in the report are:-                       Novartis Pharmaceuticals Merck KGaA Eli Lilly and Company Janssen Research & Development Hoffmann-La Roche Xcovery BeyondSpring Pharmaceuticals OSE Immunotherapeutics Sanofi Pfizer Astellas Pharma Seattle Genetics Blueprint Medicines Corporation Takeda AbbVie Kadmon Corporation Amgen Symphogen Regeneron Pharmaceuticals Peregrine Pharmaceuticals Avid Bioservices GlaxoSmithKline And many others The report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD- L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well. Market Driver

4. Request Sample Page @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer- pipeline-insight Market Barrier Key Questions Answered  What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Non-Small Cell Lung Cancer? What are the key findings pertaining to the Non-Small Cell Lung Cancer epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)? What would be the total number of patients of Non-Small Cell Lung Cancer across the 7MM during the forecast period (2017-2030)? Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)? At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)? What is the disease risk, burden and unmet needs of the Non-Small Cell Lung Cancer? What are the currently available treatments of Non-Small Cell Lung Cancer?       Reasons to buy   The Non-Small Cell Lung Cancer Epidemiology report will allow the user to - Develop business strategies by understanding the trends shaping and driving the global Non- Small Cell Lung Cancer market Quantify patient populations in the global Non-Small Cell Lung Cancer market to improve product design, pricing, and launch plans Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-Small Cell Lung Cancer therapeutics in each of the markets covered  

5.   Understand the magnitude of Non-Small Cell Lung Cancer population by its epidemiology The Non-Small Cell Lung Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources Key Assessments     Patient Segmentation Disease Risk and Burden Risk of disease by the segmentation Factors driving growth in a specific patient population Request Sample Page @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer- pipeline-insight Table of Contents 1. Report Introduction 2. Non-Small Cell Lung Cancer 2.1. Overview 2.2. History 2.3. Non-Small Cell Lung Cancer Symptoms 2.4. Causes 2.5.Pathophysiology 2.6. Non-Small Cell Lung Cancer Diagnosis 2.6.1. Diagnostic Guidelines 3. Non-Small Cell Lung Cancer Current Treatment Patterns 3.1. Non-Small Cell Lung Cancer Treatment Guidelines 4. Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective 4.1. In-depth Commercial Assessment 4.1.1. Non-Small Cell Lung Cancer companies collaborations, Licensing, Acquisition -Deal Value Trends

6. 4.1.1.1. Assessment Summary 4.1.2. Non-Small Cell Lung Cancer Collaboration Deals 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis 4.1.2.3. Non-Small Cell Lung Cancer Acquisition Analysis 5. Therapeutic Assessment 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development 5.1.2. Assessment by Product Type (Mono / Combination) 5.1.2.1. Assessment by Stage and Product Type 5.1.3. Assessment by Route of Administration 5.1.3.1. Assessment by Stage and Route of Administration 5.1.4. Assessment by Molecule Type 5.1.4.1. Assessment by Stage and Molecule Type 5.1.5. Assessment by MOA 5.1.5.1. Assessment by Stage and MOA 5.1.6. Assessment by Target 5.1.6.1. Assessment by Stage and Target 6. Non-Small Cell Lung Cancer Late Stage Products (Phase-III) 7. Non-Small Cell Lung Cancer Mid Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. Non-Small Cell Lung Cancer Discontinued Products

7. 13. Non-Small Cell Lung Cancer Product Profiles 13.1. Drug Name: Company 13.1.1. Product Description 13.1.1.1. Product Overview 13.1.1.2. Mechanism of action 13.1.2. Research and Development 13.1.2.1. Clinical Studies 13.1.3. Product Development Activities 13.1.3.1. Collaboration 13.1.3.2. Agreements 13.1.3.3. Acquisition 13.1.3.4. Patent Detail 13.1.4. Tabulated Product Summary 13.1.4.1. General Description Table Detailed information in the report? 14. Non-Small Cell Lung Cancer Key Companies 15. Non-Small Cell Lung Cancer Key Products 16. Dormant and Discontinued Products 16.1. Dormant Products 16.1.1. Reasons for being dormant 16.2. Discontinued Products 16.2.1. Reasons for the discontinuation 17. Non-Small Cell Lung Cancer Unmet Needs 18. Non-Small Cell Lung Cancer Future Perspectives 19. Non-Small Cell Lung Cancer Analyst Review

8. 20. Appendix 21. Report Methodology 21.1. Secondary Research 21.2. Expert Panel Validation Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market Related Reports:   Non-Small Cell Lung Cancer Epidemiology Forecast to 2030 Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 About DelveInsight DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.